KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Capital Expenditures (2016 - 2026)

Alnylam Pharmaceuticals filings provide 18 years of Capital Expenditures readings, the most recent being $21.8 million for Q1 2026.

  • Quarterly Capital Expenditures rose 143.4% to $21.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $71.6 million through Mar 2026, up 74.52% year-over-year, with the annual reading at $58.7 million for FY2025, 71.24% up from the prior year.
  • Capital Expenditures hit $21.8 million in Q1 2026 for Alnylam Pharmaceuticals, down from $23.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $31.3 million in Q3 2025 and bottomed at -$45.2 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $10.7 million, with a median of $15.3 million recorded in 2023.
  • Peak annual rise in Capital Expenditures hit 300.09% in 2025, while the deepest fall reached 314.67% in 2025.
  • Alnylam Pharmaceuticals' Capital Expenditures stood at -$45.2 million in 2022, then soared by 133.86% to $15.3 million in 2023, then plummeted by 40.6% to $9.1 million in 2024, then surged by 156.12% to $23.3 million in 2025, then dropped by 6.26% to $21.8 million in 2026.
  • Per Business Quant, the three most recent readings for ALNY's Capital Expenditures are $21.8 million (Q1 2026), $23.3 million (Q4 2025), and $31.3 million (Q3 2025).